Mankind Pharma Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MANKIND.NS | IPCALAB.BO | ZYDUSLIFE.BO | SUNPHARMA.BO | AUROPHARMA.NS | GRANULES.BO | |
|---|---|---|---|---|---|---|
| Market cap | 944.01B | 486.30B | 1.11T | 4.19T | 908.41B | 194.90B |
| P/E (TTM) | 46.2 | 37.1 | 24.9 | 38.4 | 24.7 | 35.7 |
| Forward P/E | 32.3 | 27.2 | 22.7 | 30.9 | 16.9 | 26.8 |
| Price/book | 5.8 | 6.0 | 4.1 | 5.4 | 2.4 | 4.9 |
| Dividend yield | — | 0.33% | 0.09% | 0.97% | — | 0.26% |
| 1-year change | −8.07% | +42.49% | +10.44% | −2.21% | +47.52% | +0.63% |
| Today | +1.43% | +5.60% | +0.39% | 0.00% | −2.63% | −0.43% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All MANKIND.NS news ›Mankind Pharma Enters Next-Generation Cancer Therapy Market With €48 Million Belgian Biotech Deal
The agreed investment is €48 million, to be paid in instalments in cash. The transaction gives Mankind a majority interest in a biotechnology business developing next-generation chimeric antigen receptor T-cell, or CAR-T, therapies.…
Mankind Pharma Sees Sharp Open Interest Surge Amid Mixed Market Signals
Such a pronounced rise in open interest alongside substantial volume suggests fresh positions are being established rather than existing ones being squared off. This typically indicates increased conviction among traders, either in…
Mankind Pharma to Back Next-Generation CAR-T Cancer Therapies
Mankind to invest EUR 48 million for 70% stake in Armed Cell Therapeutics Armed Cell Therapeutics (ACTx) has a pipeline of next-generation CAR-T assets, with lead programs in non-Hodgkin lymphoma and small cell lung cancer ACTx will pursue…
Mankind Pharma to Acquire 70% Stake in Armed Cell Therapeutics for Rs 511.4 Crore
Armed Cell Therapeutics is a Belgium-based biotechnology company focused on developing next-generation armed CAR-T therapies for cancer. Its development pipeline includes lead programmes targeting non-Hodgkin lymphoma and small cell lung…
Mankind Pharma buys majority stake in Armed Cell Therapeutics for €48 M
BioSpectrum India Mankind Pharma buys majority stake in Armed Cell Therapeutics for â¬48 M October 16, 2026 | Friday | News As a part of its long term strategy to build a global innovation-led pharmaceutical business, Mankind Pharma,…
Mankind Pharma Enters CAR-T Therapy Market with Majority Stake in Armed Cell Therapeutics
Armed Cell Therapeutics was founded by leaders with extensive experience in drug development, cell therapy and biotechnology company building. Dr. Paul Stoffels, Chair of the Board: Former Chief Executive Officer of Galapagos and former…
Mankind Pharma to Acquire 70% Stake in ACTx for 48 Million Euros
Siliconindia Mankind Pharma to Acquire 70% Stake in ACTx for 48 Million Euros
Mankind Pharma To Acquire 70% Stake In Cancer Therapy Firm ACTx, ₹511 Crore Deal Marks Entry Into Advanced Cancer Treatments
Mankind Pharma will acquire 70 percent of Belgium-based ACTx for Rs 511 crore. | Mumbai: Mankind Pharma has announced a major investment in advanced cancer treatment by agreeing to acquire a 70 per cent stake in Belgium-based Armed Cell…
Lakefront offloads CAR-T programs to Armed Cell as Mankind Pharma takes control of the Belgian startup
Lakefront Biotherapeutics, formerly Galapagos, has sold five preclinical CAR-T assets to Belgian startup Armed Cell Therapeutics for €8 million upfront, while India's Mankind Pharma has agreed to acquire 70% of the buyer for €48 million.…
Mankind Pharma to acquire 70% stake in Armed Cell Therapeutics for EUR 48 million
Mankind Pharma, through its subsidiary Mankind Pharma (Netherlands) B.V., has entered into a definitive agreement to acquire a majority stake in Armed Cell Therapeutics B.V. (ACTx), a Belgium-incorporated biotechnology company developing…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
tradingview.com5
-
medicaldialogues.in3
-
scanx.trade3
-
businessupturn.com2
-
freepressjournal.in2
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 36 articles, not a forecast.